Blood Collection for Development and Validation of Point-of-Care Diagnostic Liver Function Tests

Group K Diagnostics

Status: Enrolling

Conditions: Healthy; Liver Cirrhosis; Liver Fibrosis; Liver Diseases

Treatments: Diagnostic Test: Adult

Study type: Observational

Funder types: Industry

Identifiers

NCT05457543

GKD001

Details and patient eligibility

About

This is an observational study exploring the performance of a novel point-of-care diagnostic testing platform designed to quantitate the presence of liver function biomarkers such as bilirubin. Blood samples will be collected from participants to further development and validation of the testing platform to support FDA review. The diagnostic device is intended to provide rapid in-office test results using a finger stick of blood, a reaction test device, and a smartphone app.

Full description

The nature of outpatient diagnostics delays diagnosis and proper treatment due to the need to travel to a sample collection site that is designed for volume testing adding the individual's sample to the testing que. The physical and temporal separation of diagnostic testing from medical office or virtual care visits delays physician decision-making until results are available. Many patients even skip the recommended testing due to time and financial costs.

Many acute and chronic conditions result in disruption of normal liver function. Common prescription and over-the-counter medications also affect liver function when taken over extended periods or at elevated doses. Having multiple rapid, easy-to-use diagnostic tests on a single platform could improve condition diagnosis and medication monitoring by ensuring current test results are available every time and anywhere they could be useful for immediate medical decision-making.

This study will provide fresh blood samples for further development and validation of a novel point-of-care diagnostic testing platform. Tests for liver function biomarkers such as bilirubin, ALT (alanine transaminase), and AST (aspartate aminotransferase) will be characterized and validated using fresh whole blood, freshly prepared serum, and frozen serum. Enrolled participants will have a standard venous and a standard finger stick blood collection. Enrolled participants can return once weekly for blood draws or can chose to have only a single study visit. The study will continue until sufficient data has been generated to support review of the tests by the FDA.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 18 years of age and older
• Able to read and understand an informed consent form written in English

Exclusion criteria

• Pregnancy
• Participated in the present study within the last 6 days
• Subject is subjectively unwell at the time of enrollment visit
• Subject previously participated and has asked to be withdrawn from the study

Trial design

150 participants in 1 patient group

Adult

Description:

A venous blood and capillary blood collection is taken from each participant and tested with investigative diagnostic tests.

Treatment:

Diagnostic Test: Adult